In January 2009, a paper by our group presented data on patients with PTCL who were treated with upfront myeloablative radiochemotherapy and autoSCT following four to six cycles of conventional chemotherapy.11 For this prospective study, 83 patients were enrolled, excluding ALK-positive ALCL as well as PCTL. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.